Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 153

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 1
Chunk 153
---
 developments relating to our licensed patents or other proprietary rights or those of our competitors;

			●

			governmental regulation and legislation;

			●

			change in securities analysts’ estimates of our performance, or failure to meet analysts’ expectations;

			●

			the terms and timing of any future collaborative, licensing or other arrangements that we may establish;

			●

			our ability to raise additional capital to carry through with our development plans and current and future operations;

			●

			the timing of achievement of, or failure to achieve, our manufacturing, pre-clinical, clinical, regulatory and other milestones, such as the commencement of clinical development, the completion of a clinical trial or the receipt of regulatory approval;

			●

			actions taken by regulatory agencies with respect to our product candidates;

			●

			uncontemplated problems in the supply of the raw materials used to produce our product candidates;

			●

			introductions or announcements of technological innovations or new products candidates by us, our potential future collaborators, or our competitors, and the timing of these introductions or announcements;

			●

			market conditions for equity investments in general, or the biotechnology or pharmaceutical industries in particular;

37

			●

			actual or anticipated fluctuations in our results of operations;

			●

			hedging or arbitrage trading activity that may develop regarding our common shares;

			●

			regional or worldwide recession;

			●

			sales of our common shares by our executive officers, directors and significant shareholders;

			●

			changes in accounting principles; and

			●

			the loss of any of our key scientific or management personnel.

Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common shares. In the past, following periods of volatility in the market price of a company’s securities, shareholders have often instituted class action securities litigation. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation.

If we fail to meet all applicable Nasdaq Capital Market requirements and Nasdaq determines to delist our common shares, the delisting could adversely affect the market liquidity of our common shares and the market price of our common shares could decrease and our ability to access the capital markets could be negatively